Sermorelin
Sermorelin (10mg)
$100USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.211
Reference number
10mg
Lyophilized vial
Synthetic analog of growth hormone-releasing hormone. The first 29 amino acids of the 44-amino-acid GHRH sequence.
Origin
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids (1-29) of human growth hormone-releasing hormone (GHRH). GHRH was first isolated and characterized independently by Roger Guillemin and Andrew Schally in 1982, work that built on their earlier Nobel Prize-winning research on hypothalamic hormones.
Research Lineage
Sermorelin was developed for clinical use by Serono Laboratories and received FDA approval in 1997 under the brand name Geref for diagnostic evaluation of pituitary GH secretion. Clinical studies by Vittone et al. and Khorram et al. investigated its effects on GH axis activity, body composition, and sleep quality in aging research populations.
Mechanism of Action
Sermorelin binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone through a cAMP-dependent signaling pathway. Unlike exogenous GH administration, it preserves the physiological feedback loop of the GH-IGF-1 axis.
Structural Notes
29-amino-acid peptide. Corresponds to hGHRH(1-29)-NH2. Molecular weight: 3357.96 Da. C-terminally amidated for enhanced stability.
Key References
Guillemin R et al. Science. 1982;218(4572):585-7.
Vittone J et al. J Clin Endocrinol Metab. 1997;82(5):1472-9.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.